Study ID: AMGEN 386 Study 20060517
Description:

Phase 3, Randomized, Double-blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Following a Prior Platinum-Containing Regimen

Location:
Sioux Falls Region,Sanford Health
Principal Investigator:
Maria Bell MD
Disease:
Ovary/Fallopian Tube/Primary Peritoneal
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list